(Q43082885)

13 November 2017

title

Antiangiogenic therapy in myelodysplastic syndromes: is there a role? (English)

1 reference

13 November 2017

main subject

angiogenesis inhibitor

1 reference

Stephen T Oh

1

1 reference

13 November 2017

Jason Gotlib

series ordinal

2

1 reference

13 November 2017

publication date

1 January 2008

1 reference

Current hematologic malignancy reports

13 November 2017

published in

1 reference

13 November 2017

volume

3

1 reference

13 November 2017

issue

1

1 reference

13 November 2017

page(s)

10-18

1 reference

Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity

13 November 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11899-008-0003-0

Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.

21 January 2018

1 reference

12 December 2020

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

12 December 2020

Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro

1 reference

12 December 2020

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

1 reference

12 December 2020

Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia.

1 reference

12 December 2020

The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

1 reference

12 December 2020

Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes

1 reference

12 December 2020

Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo

1 reference

12 December 2020

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

1 reference

12 December 2020

Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown

1 reference

12 December 2020

Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Ras and myelodysplasia: lessons from the last decade.

1 reference

12 December 2020

Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes

1 reference

12 December 2020

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

1 reference

12 December 2020

Thalidomide for the treatment of patients with myelodysplastic syndromes

1 reference

12 December 2020

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

1 reference

12 December 2020

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

1 reference

12 December 2020

The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.

1 reference

12 December 2020

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia

1 reference

12 December 2020

Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-alpha in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density

1 reference

12 December 2020

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

1 reference

12 December 2020

Evidence of increased angiogenesis in patients with acute myeloid leukemia

1 reference

12 December 2020

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

12 December 2020

Tumor angiogenesis: therapeutic implications

1 reference

12 December 2020

KDR receptor: a key marker defining hematopoietic stem cells

1 reference

12 December 2020

Bevacizumab--current status and future directions

1 reference

12 December 2020

Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.

1 reference

12 December 2020

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications

1 reference

12 December 2020

Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study

1 reference

12 December 2020

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome

1 reference

12 December 2020

Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes

1 reference

12 December 2020

Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

1 reference

12 December 2020

Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells

1 reference

12 December 2020

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

12 December 2020

Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies

1 reference

12 December 2020

Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.

1 reference

12 December 2020

Bone marrow angiogenesis in multiple myeloma

1 reference

12 December 2020

Angiogenesis in life, disease and medicine

1 reference

12 December 2020

Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes

1 reference

12 December 2020

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

1 reference

12 December 2020

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

1 reference

12 December 2020

Vascular endothelial growth factor is a secreted angiogenic mitogen

1 reference

12 December 2020

p21ras is modified by a farnesyl isoprenoid

1 reference

12 December 2020

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes

1 reference

12 December 2020

A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies

1 reference

12 December 2020

Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome

1 reference

12 December 2020

The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.

1 reference

12 December 2020

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

12 December 2020

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

12 December 2020

Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.

1 reference

12 December 2020

Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial

1 reference

12 December 2020

Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis

1 reference

12 December 2020

Angiogenesis in myelodysplastic syndromes

1 reference

12 December 2020

Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category

1 reference

12 December 2020

Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy.

1 reference

12 December 2020

Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes

1 reference

12 December 2020

Mechanisms of action of arsenic trioxide.

1 reference

12 December 2020

Prognostic value of bone marrow angiogenesis in multiple myeloma

1 reference

12 December 2020

Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis

1 reference

12 December 2020

10.1007/S11899-008-0003-0

Identifiers

DOI

1 reference

13 November 2017

1 reference